CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Moderna, CytomX announce mRNA collaboration

(Reuters) - Moderna Inc on Thursday said it will collaborate with CytomX Therapeutics for the development of certain investigational messenger RNA-based therapies. (Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Collaboration will combine Moderna’s mRNA technology with CytomX’s Probody® Platform to generate and develop therapeutics for oncology and non-oncology...

MODERNA AND CYTOMX ANNOUNCE STRATEGIC RESEARCH COLLABORATION FOR MRNA-BASED CONDITIONALLY ACTIVATED THERAPEUTICS

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced a collaboration and licensing agreement to create investigational ...

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments CAMBRIDGE, MA and SOUTH SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) thera

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Green Stock News for the New Green Economy.